Replimune Group, Inc. (NASDAQ:REPL) Stock Holdings Lifted by Tang Capital Management LLC

Tang Capital Management LLC raised its position in Replimune Group, Inc. (NASDAQ:REPL) by 125.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,700,000 shares of the company’s stock after purchasing an additional 1,500,000 shares during the quarter. Replimune Group makes up approximately 2.2% of Tang Capital Management LLC’s holdings, making the stock its 10th biggest position. Tang Capital Management LLC owned about 3.95% of Replimune Group worth $32,697,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of REPL. Boxer Capital Management LLC purchased a new position in Replimune Group in the fourth quarter valued at about $21,754,000. Price T Rowe Associates Inc. MD grew its stake in Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. MPM Bioimpact LLC purchased a new position in Replimune Group in the fourth quarter valued at about $11,504,000. RTW Investments LP grew its stake in Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after purchasing an additional 931,223 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Replimune Group in the fourth quarter valued at about $10,853,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

NASDAQ REPL opened at $7.85 on Friday. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market capitalization of $604.57 million, a PE ratio of -2.56 and a beta of 0.68. The stock has a 50-day simple moving average of $8.95 and a 200 day simple moving average of $11.32.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on REPL shares. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. BMO Capital Markets upped their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. upped their price target on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average target price of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.